Osteoporosis is the most common metabolic bone disorder, and is characterized by low bone mass accompanied by microarchitectural deterioration of bone tissue.
The consequent increase in bone fragility results in osteoporosis patients being prone to sustaining fractures.
Although the majority of osteoporosis patients are postmenopausal women, it is not a female-only disease. It is estimated that one in three women and one in five men aged over 50 years will sustain an osteoporosis-related fracture.
Prolia will drive growth of the US market, while Forteo losses will halt growth in Japan and the EU.
The oral bisphosphonate alendronate dominates the treatment of all severities of low bone mass.
Forecasted growth in the total prevalence of osteopenia and osteoporosis will be driven by aging populations.
Biosimilar erosion and new anabolic entrants with superior efficacy are set to erode Forteo's blockbuster sales.
The arrival of Amgen's Evenity will be delayed due to safety issues.
Key Topics Covered:
FORECAST: OSTEOPOROSIS Overview Executive Summary Market Overview And Trends Market Definition And Methodology Actonel Boniva Duavee Edirol Evenity Evista Forteo And Movymia Fosamax Prolia Reclast Tymlos Primary Research Methodology
TREATMENT: OSTEOPOROSIS Overview Executive Summary Primary Research Methodology Disease Definition And Diagnosis Patient Segmentation Current Treatment Options Prescribing Trends Treatment Trends In Osteopenia Treatment Trends In Osteoporosis Treatment Trends In Severe Osteoporosis Compliance Rates Unmet Needs In Osteoporosis